Proveca Expands Cardiology Portfolio through Licensing Agreement with Wockhardt UK

This press release is intended for investors only.

Proveca is delighted to announce that on the 20th of March 2024, an agreement was reached with Wockhardt UK for the licensing and supply of a Captopril oral solution, marking a pivotal expansion in Proveca’s cardiology portfolio.

Captopril oral solution is an ACE inhibitor widely used in heart failure and other indications, including hypertension and Type I diabetic nephropathy. The addition of Captopril to Proveca’s cardiology portfolio holds significant business benefits and aligns with the existing cardiology product. This addition will further facilitate market development and expansion.

Proveca has secured the licensing rights for the UK, Ireland, Netherlands, Germany, Austria, France, Italy, Denmark, Finland, Norway, and Sweden. The medication will be launched in the UK this year following the granting of a marketing authorisation to Proveca, with European market launches to swiftly follow.

Dr Simon Bryson, CEO, Proveca: “We are delighted to announce this agreement and welcome the addition of a second product to our Cardiology portfolio. We look forward to extending the medication’s reach to benefit patients across the licensed territories.” 

Ravi Limaye, Managing Director, Wockhardt UK: “As a company, we are very excited to partner with Proveca in supplying Captopril oral solution to more cardiology patients in need.  This is another example of Wockhardt UK’s commitment to improving access to high quality medicines where they are needed the most.”


The Summary of Product Characteristics (SmPCs) of Captopril (Wockhardt UK Ltd) can be found on the emc website.

Captopril 5mg/5ml Oral Solution (POM):

Captopril 25mg/5ml Oral Solution (POM):


About Proveca

Proveca is a global pharmaceutical company that specialises in the development and licensing of medicines to address the unmet medical needs of children.

Working with clinicians, parents, carers and children, Proveca are leading the way to provide licensed medicines that are tailored to children’s specific requirements.

For further information about Proveca, please visit




May 2024